Insulet Corporation (PODD)

Market Cap	22.77B
Revenue (ttm)	2.20B
Net Income (ttm)	402.20M
Shares Out	70.37M
EPS (ttm)	5.55
PE Ratio	58.32
Forward PE	72.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	427,790
Open	324.04
Previous Close	323.55
Day's Range	322.55 - 325.26
52-Week Range	171.61 - 329.33
Beta	1.27
Analysts	Buy
Price Target	309.56 (-4.33%)
Earnings Date	May 8, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Forecast

According to 18 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $309.56, which is a decrease of -4.33% from the latest price.

Price Target

$309.56

(-4.33% downside)

Analyst Consensus: Buy